Does randomization matter in rare disease clinical trials
Stephanie Wied, Denis Kirilov Razsolkov, Nicole Heussen, Ralf-Dieter Hilgers · 2026
Read Does randomization matter in rare disease clinical trials by Stephanie Wied, Denis Kirilov Razsolkov, Nicole Heussen, Ralf-Dieter Hilgers (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0339427.txt.
Description
Stephanie Wied and colleagues ask how much the way patients are split into trial groups matters when diseases are rare and patient numbers tiny. Random splitting guards against bias, but with few patients, some splitting methods guess easily or stack groups unfairly. The team offers guidance built on an evaluation framework and a free software tool that scores splitting methods on bias, predictability, and error rates for a given trial design.
Judged one measure at a time, different methods can look best, which the authors warn is misleading; the full scorecard must be read together. No single method wins for every design. Wied and colleagues aim their guidance at trial designers who must defend their choice to regulators when every patient counts.
Catalog record
| CREATOR | Stephanie Wied, Denis Kirilov Razsolkov, Nicole Heussen, Ralf-Dieter Hilgers |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51291 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |